Human immunodeficiency virus type 1 infection

Active Ingredient: Rilpivirine

Indication for Rilpivirine

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Rilpivirine, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 12 years of age and older with a viral load ≤100,000 HIV-1 RNA copies/ml.

Genotypic resistance testing should guide the use of rilpivirine.

For this indication, competent medicine agencies globally authorize below treatments:

25 mg once daily

For:

Dosage regimens

Oral, 25 milligrams rilpivirine, once daily to meals.

Detailed description

The recommended dose of rilpivirine is 25 mg taken once daily.

Dose adjustment

For patients concomitantly receiving rifabutin, the rilpivirine dose should be increased to 50 mg taken once daily. When rifabutin co-administration is stopped, the rilpivirine dose should be decreased to 25 mg once daily.

Missed dose

If the patient misses a dose of rilpivirine within 12 hours of the time it is usually taken, the patient must take the medicine with a meal as soon as possible and resume the normal dosing schedule. If a patient misses a dose of rilpivirine by more than 12 hours, the patient should not take the missed dose, but resume the usual dosing schedule.

If a patient vomits within 4 hours of taking the medicine, another rilpivirine dose should be taken with a meal. If a patient vomits more than 4 hours after taking the medicine, the patient does not need to take another dose of rilpivirine until the next regularly scheduled dose.

Elderly

There is limited information regarding the use of rilpivirine in patients >65 years of age. No dose adjustment of rilpivirine is required in older patients. Rilpivirine should be used with caution in this population.

Dosage considerations

Rilpivirine must be taken with a meal.

Active ingredient

Rilpivirine

Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ.

Read more about Rilpivirine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.